Torqur AG, a clinical-stage biotechnology company and subsidiary of Swiss Rockets dedicated to advancing treatments for oncology and dermatology, and Lonza, a contract development and manufacturing organization (CDMO), have signed an agreement for the clinical supply of bimiralisib, an investigational therapy being explored across multiple indications. AK is a common pre‑cancerous skin condition caused by chronic sun exposure and represents the leading precursor to cutaneous squamous cell car...